IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.460
AS - Asia 4.314
EU - Europa 2.489
SA - Sud America 858
AF - Africa 268
Continente sconosciuto - Info sul continente non disponibili 208
OC - Oceania 2
Totale 12.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.319
SG - Singapore 1.748
CN - Cina 693
VN - Vietnam 656
BR - Brasile 647
IE - Irlanda 586
IT - Italia 472
SE - Svezia 454
BD - Bangladesh 393
HK - Hong Kong 364
FR - Francia 194
DE - Germania 181
ZA - Sudafrica 176
NL - Olanda 149
AT - Austria 115
FI - Finlandia 81
IN - India 74
AR - Argentina 73
RU - Federazione Russa 62
CA - Canada 60
GB - Regno Unito 55
IR - Iran 46
TR - Turchia 46
IQ - Iraq 44
ID - Indonesia 42
EC - Ecuador 36
MX - Messico 35
CO - Colombia 31
BE - Belgio 24
JP - Giappone 24
VE - Venezuela 22
PH - Filippine 20
PK - Pakistan 20
MA - Marocco 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
PL - Polonia 18
PY - Paraguay 18
KR - Corea 17
UA - Ucraina 15
CI - Costa d'Avorio 13
EG - Egitto 13
ES - Italia 13
KE - Kenya 12
LT - Lituania 11
MY - Malesia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
TW - Taiwan 9
DO - Repubblica Dominicana 8
JO - Giordania 8
TH - Thailandia 8
BO - Bolivia 7
NP - Nepal 7
PE - Perù 7
TN - Tunisia 7
UY - Uruguay 7
CR - Costa Rica 6
EE - Estonia 6
BG - Bulgaria 5
ET - Etiopia 5
HN - Honduras 5
JM - Giamaica 5
OM - Oman 5
PA - Panama 5
SN - Senegal 5
AL - Albania 4
AO - Angola 4
AZ - Azerbaigian 4
DZ - Algeria 4
KW - Kuwait 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
SV - El Salvador 4
BH - Bahrain 3
GT - Guatemala 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
NG - Nigeria 3
QA - Qatar 3
AU - Australia 2
CH - Svizzera 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
KN - Saint Kitts e Nevis 2
MD - Moldavia 2
NI - Nicaragua 2
PR - Porto Rico 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
CD - Congo 1
CV - Capo Verde 1
Totale 12.371
Salva come PNG Salva come JPEG
Città #
Singapore 828
Ashburn 611
Dublin 580
San Jose 498
Chandler 462
Hong Kong 356
Santa Clara 338
Council Bluffs 237
Ho Chi Minh City 211
Boardman 186
Dallas 172
Beijing 170
Johannesburg 156
Hanoi 150
New York 128
Lauterbourg 123
Princeton 113
Vienna 109
Shanghai 106
Los Angeles 96
Ann Arbor 79
Munich 69
São Paulo 62
Milan 58
Helsinki 55
Buffalo 42
Tehran 38
Rome 34
Columbus 31
Frankfurt am Main 31
Parma 31
Rio de Janeiro 31
Moscow 30
Bremen 28
Chicago 28
Wilmington 26
Bologna 25
Da Nang 25
Des Moines 25
Turku 25
The Dalles 24
Jakarta 23
Brussels 22
Haiphong 22
Phoenix 22
Nuremberg 21
Toronto 20
Orem 19
Belo Horizonte 18
Brooklyn 18
Guangzhou 16
Guayaquil 16
London 16
Naples 16
Seattle 16
Atlanta 15
Stockholm 15
Tashkent 15
Baghdad 14
Boston 14
Brasília 14
Hefei 14
Tianjin 14
Warsaw 14
Abidjan 13
Chennai 13
Houston 13
Tokyo 13
Curitiba 12
Dearborn 12
Montreal 12
Quito 12
Hải Dương 11
Asunción 10
Denver 10
Düsseldorf 10
Marseille 10
Nanjing 10
Brno 9
Lahore 9
Medellín 9
Modena 9
Nairobi 9
Vancouver 9
Verona 9
Ankara 8
Bari 8
Biên Hòa 8
Charlotte 8
Dhaka 8
Pasadena 8
Poplar 8
Pune 8
San Francisco 8
Sorocaba 8
Bogotá 7
Borås 7
Buenos Aires 7
Bắc Ninh 7
Figino 7
Totale 7.160
Salva come PNG Salva come JPEG
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 208
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 199
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 195
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 193
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 183
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 179
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 177
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 177
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 160
Review on radiological evolution of COVID-19 pneumonia using computed tomography 160
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 155
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 155
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 154
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 147
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 146
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 145
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 141
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 139
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 139
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 138
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 136
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 131
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 127
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 121
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 121
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 120
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients 118
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 118
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 116
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 116
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 115
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 115
The effect of COVID-19 emergency in the management of melanoma in Italy 113
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 113
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 112
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 111
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 111
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 110
Renal cell carcinoma and viral infections: A dangerous relationship? 110
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 109
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 109
Avelumab Maintenance for Urothelial Carcinoma 107
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 107
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 105
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 103
Cabozantinib in RCC: only a METEOR or a rising star? 103
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 101
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 101
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 100
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 100
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 99
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 99
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 99
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 98
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study 98
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 97
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 95
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 95
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 95
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 94
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 94
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 93
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 92
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 92
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 91
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 89
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 87
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 86
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 85
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 85
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 84
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 84
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 84
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 84
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 83
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 82
Reassessing Human Adipose Tissue 82
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 80
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 78
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 76
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 76
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 76
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 75
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 75
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 74
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 73
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 73
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 72
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma 72
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 72
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 71
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 71
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 71
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 70
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 70
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 70
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 69
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 68
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a) 67
Totale 10.860
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.505
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022530 0 14 13 24 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/20252.642 38 154 195 111 226 351 128 120 263 346 199 511
2025/20265.999 472 476 638 601 846 248 550 171 672 493 520 312
2026/2027341 151 190 0 0 0 0 0 0 0 0 0 0
Totale 12.599